Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients
Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study Of ISIS 681257 Subcutaneous Injections In Male And Female Subjects With Normal And Impaired Renal Function
Sponsor: Akcea Therapeutics
A PHASE1 clinical study on Renal Impairment, this trial is completed. The trial is conducted by Akcea Therapeutics and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Nov 2018 — Jun 2019 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Akcea Therapeutics
- Ionis Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .